Our Technology

The Covonix Lumivir™ multimodal solution combines low light level luminometry on saliva samples in combination with method 1, method 2, method 3 and method 4. The first generation test is designed to aid in the diagnosis and management of an infection. The second generation test will leverage COVID-19 specific capture and detection antibodies to enable diret antigen detection at the point of care. Data is collected locally by the instrument and transferred by Bluetooth LE to a mobile app where the data is encrypted and uploaded to a cloud based server for report generation and combination with EHR and contact tracing. The reports can then be sent to telehealth physicians for interpretation and then provided to nurses and other field clinicians to assist in the identification and management of COVID-19, for instance making ‘Return-to-Work’ and ‘Return-to-School’ decisions.

When a swab or saliva sample of a patient is exposed to chemical reagents, light is produced indicating an abnormally elevated level of a key protein, indicative of an infection. In a second geneartion, COVID-19 specific antibodies are used to capture minute quantities of virus while detection antibodies are conjugated with reporter enzymes so that light can be used as a readout for the presence of the virus. Because luminometers leverage low light level pn and PIN photodiodes, the delicate photo-currents can be converted into measureable signals which can be integrated, quantified, transferred and analyzed by the local app and cloud based report analytics.

For more information please see this Scholarpedia article.

At Covonix, we believe that rapid point of care luminometry in combination with other symptom measurements is the solution to massive daily testing for COVID-19 to open up both our nations and the world’s economies.

Method 1

A number of neuropsychological tests, including reaction time tests, are well validated measures to assess multiple cognitive domains of a person, including memory, neuro-ocular motor function, and speech. Building on this clinical literature, Cerora’s platform includes a number of these tasks like reaction time tests and immediate word recall tests and novel computer-based neuropsychological tasks like an improved neuro-ophthalmological saccade task that involves prefrontal cortex functions including working memory. Cerora will be submitting Borealis for review by FDA and other applicable regulatory authorities. When cleared or approved for marketing, Borealis will include similar neurological assessment tasks in combination with objective biosensor-based measurements.

Method 2

Self-reported psychological impressions are subjective, but remain at the core of clinical assessment tools for diagnosing brain-related injury and cognitive disorders. The Cerora platform includes a number of validated symptom checklists to aid in assessing the status of brain-health in school-age children, adults, and seniors. Cerora will be submitting Borealis for review by FDA and other applicable regulatory authorities. When cleared or approved for marketing, Borealis will include self-report inventories in combination with objective biosensor measurements.

Method 3

Self-reported psychological impressions are subjective, but remain at the core of clinical assessment tools for diagnosing brain-related injury and cognitive disorders. The Cerora platform includes a number of validated symptom checklists to aid in assessing the status of brain-health in school-age children, adults, and seniors. Cerora will be submitting Borealis for review by FDA and other applicable regulatory authorities. When cleared or approved for marketing, Borealis will include self-report inventories in combination with objective biosensor measurements.

Method 4

Self-reported psychological impressions are subjective, but remain at the core of clinical assessment tools for diagnosing brain-related injury and cognitive disorders. The Cerora platform includes a number of validated symptom checklists to aid in assessing the status of brain-health in school-age children, adults, and seniors. Cerora will be submitting Borealis for review by FDA and other applicable regulatory authorities. When cleared or approved for marketing, Borealis will include self-report inventories in combination with objective biosensor measurements.